Crescendo Biologics stock price, funding rounds, valuation and financials

Crescendo Biologics has raised $116.2 m in total funding. Crescendo Biologics annual revenue was £7.51 m in FY 2018

£7.5 M

Crescendo Biologics Revenue FY, 2018
Crescendo Biologics Gross profit (FY, 2018)7.5 M
Crescendo Biologics Gross profit margin (FY, 2018), %100%
Crescendo Biologics Net income (FY, 2018)-1.8 M
Crescendo Biologics EBIT (FY, 2018)-2.2 M
Crescendo Biologics Cash, 31-Dec-201824.8 M
Get notified regarding key financial metrics and revenue changes at Crescendo BiologicsLearn more
Banner background

Crescendo Biologics Revenue

Crescendo Biologics revenue was £7.51 m in FY, 2018

Embed Graph

Crescendo Biologics Funding

Summary Metrics

Founding Date

2007

Crescendo Biologics total Funding

$116.2 m

Crescendo Biologics latest funding size

$70 m

Time since last funding

4 years ago

Crescendo Biologics investors

Crescendo Biologics's latest funding round in April 2018 was reported to be $70 m. In total, Crescendo Biologics has raised $116.2 m

Crescendo Biologics Capital Raised

Embed Graph

Crescendo Biologics Income Statement

Annual

GBPFY, 2016FY, 2017FY, 2018

Revenue

758.3k1.8m7.5m

Gross profit

758.3k1.8m7.5m

Gross profit Margin, %

100%100%100%

Depreciation and amortization

313.2k513.3k621.3k

EBIT

(5.5m)(8.1m)(2.2m)

EBIT margin, %

(723%)(449%)(30%)

Interest expense

4.2k

Interest income

31.3k48.0k99.4k

Pre tax profit

(5.5m)(10.9m)(3.0m)

Income tax expense

(1.1m)(1.4m)(1.2m)

Net Income

(4.3m)(9.5m)(1.8m)

Crescendo Biologics Balance Sheet

Annual

GBPFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.3m894.8k2.1m331.6k3.0m2.7m4.3m7.0m24.8m

Accounts Receivable

530.0k704.1k

Current Assets

2.4m950.9k2.9m766.0k6.2m10.7m5.8m9.8m28.5m

PP&E

61.0k74.4k122.9k119.0k465.3k1.1m1.0m1.4m1.6m

Total Assets

12.0m6.9m11.3m30.1m

Accounts Payable

83.7k41.6k110.7k80.9k203.1k903.9k477.3k523.5k1.3m

Short-term debt

15.1m72.2k

Current Liabilities

195.3k203.6k4.8m5.3m354.5k1.5m748.2k16.4m3.0m

Long-term debt

77.6k

Non-Current Liabilities

4.7m4.7m77.6k

Total Debt

15.1m149.8k

Total Liabilities

1.5m748.2k16.4m3.1m

Common Stock

52.052.05.05.0169.0260.0260.0267.0992.0

Retained Earnings

(2.0m)(3.6m)(6.5m)(9.1m)(10.1m)(15.8m)(20.2m)(31.5m)(33.5m)

Total Equity

2.5m1.0m(6.4m)(9.0m)6.4m10.5m6.2m(5.1m)27.0m

Financial Leverage

1.1 x1.1 x-2.2 x1.1 x

Crescendo Biologics Cash Flow

Annual

GBPFY, 2015FY, 2016FY, 2017FY, 2018

Cash From Operating Activities

(5.2m)(4.7m)(7.2m)167.3k

Cash From Investing Activities

(4.9m)(175.1k)(365.2k)(418.3k)

Cash From Financing Activities

9.8m3.9k18.1m

Net Change in Cash

(321.9k)(4.9m)(7.6m)17.8m

Crescendo Biologics Ratios

GBPFY, 2010